ANTICOV Trial Finds Nitazoxanide/Ciclesonide Drug Combination Does Not Reduce Hospitalisation Risk in Patients With Mild COVID-19

ANTICOV, News, ANTICOV, NCT04920838, Feb 2022
Progression -104% improvement lower risk ← → higher risk Nitazoxanide  ANTICOV  EARLY TREATMENT RCT Is early treatment with nitazoxanide + ciclesonide beneficial? RCT 1,148 patients in multiple countries Trial compares with paracetamol, results vs. placebo may differ Higher progression with treatment (not stat. sig., p=0.092) c19early.org ANTICOV, News, February 2022 0 0.5 1 1.5 2+ RR
RCT with 591 nitazoxanide/ciclesonide and 557 paracetamol patients, up to 7 days from onset, showing higher progression, without statistical significance.
risk of progression, 104.3% higher, RR 2.04, p = 0.09, treatment 16 of 591 (2.7%), control 7 of 557 (1.3%), adjusted per study, odds ratio converted to relative risk, SpO2 ≤93 or death, day 21, Table 13.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
ANTICOV et al., 28 Feb 2022, Randomized Controlled Trial, multiple countries, preprint, 1 author, this trial compares with another treatment - results may be better when compared to placebo, this trial uses multiple treatments in the treatment arm (combined with ciclesonide) - results of individual treatments may vary, trial NCT04920838 (history) (ANTICOV).
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit